PennyTrader.com Presents Today’s Midday Stock Report: MDHI, CPRX, CERP
Stocks continue to slide lower as markets trade on session lows. A loss of 1.7% has the Nasdaq leading the decline while both the S&P 500 and Dow outperform with respective losses of 0.8% and 1.1%.
Hotel stocks are seeing selling this morning after Marriott International (MAR 36.21, -1.82) reported in-line earnings per share of $0.42, and announced revenues fell 6.6% year over year to $2.78 billion which missed the Capital IQ Consensus Estimate of $2.84 billion. Notable was the weakness in markets outside of North America as business in both the Middle East and Asia saw a slowdown in the luxury market. The company’s full-year 2012 guidance earnings per share guidance was in-line with expectations at $1.65-1.75. Peers Starwood Hotels & Resorts Worldwide (HOT 49.39, -1.99) and Hyatt Hotels (H 34.83, -0.92) are both lower as they piggyback losses.
MDHI - Trade Alert
Up 45.83% in morning trading to $.0035 with 6M shares traded
Medical Alarm Concepts Holdings, Inc. (MAC) develops and manufactures innovative products and practical solutions within the framework of a vast growing marketplace. MediPendant’s™ patented two-way voice technology enables the user to speak and listen directly through the pendant no matter where the user may be in and around their home. MediPendant™ service also includes advanced features such as three-way calling that enables the operator to link loved ones directly into the emergency call in real time. Text message alerts are also standard, and are used to inform loved ones that the user has contacted an operator or has requested assistance. Medical Alarm Concepts Holding, Inc. (MDHI.PK) today announced significant upgrades to its service offerings for the customers of the nation’s second largest retailer and largest warehouse club chain. These enhancements include contract extensions options and new enhanced concierge services, which will provide unparalleled levels of services for MediPendant customers.
To Read Full Story go to: http://www.pennytrader.com/
********************
CPRX – News Alert
Up 28.71% in morning trading to $.8236 with 1M shares traded
Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases and disorders of the central nervous system, including addiction and epilepsy. Catalyst has two products in development, CPP-109 and CPP-115. It is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109, for the treatment of cocaine addiction. Both CPP-109 and CPP-115 have been granted “Fast Track” status by the FDA for the treatment of cocaine addiction. Catalyst is also planning to evaluate CPP-109 for the treatment of other addictions. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to the inhibition of GABA aminotransferase. Catalyst Pharmaceutical Partners, Inc. (CPRX) today announced that it expects to report top-line results from its CPP-109 (vigabatrin) Phase II(b) trial around the end of September 2012 versus the previous guidance of early in the first quarter of 2013.
To Read Full Story go to: http://www.pennytrader.com/
********************
CERP – News Alert
Up 34.31% in morning trading to $.4101 with 300K shares traded
Cereplast, Inc. designs and manufactures proprietary biobased, sustainable bioplastics which are used as substitutes for traditional plastics in all major converting processes – such as injection molding, thermoforming, blow molding and extrusions – at a pricing structure that is competitive with traditional plastics. On the cutting-edge of biobased plastic material development, Cereplast now offers resins to meet a variety of customer demands. Cereplast Compostables(R) resins are ideally suited for single-use applications where high biobased content and compostability are advantageous, especially in the food service industry. Cereplast Sustainables(R) resins combine high biobased content with the durability and endurance of traditional plastic, making them ideal for applications in industries such as automotive, consumer electronics and packaging. Cereplast, Inc. (CERP) today announced that it has entered into a distribution agreement with Hamburg, Germany-based ALBIS PLASTIC GMBH to supply Cereplast bioplastic resins to the United Kingdom and Ireland.
To Read Full Story go to: http://www.pennytrader.com/
********************
To Follow PennyTrader on Twitter: http://twitter.com/pennytrader
To Join Our Facebook Page: http://www.facebook.com/PennyTrader2
PennyTrader.com, PO Box 791, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@PennyTrader.com.This email address is being protected from spam bots, you need Javascript enabled to view it
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on PennyTrader.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
Leave a Comment